Innospec IOSP Issue of shares upon vesting of restricted stock units (in shares)

Issue of shares upon vesting of restricted stock units (in shares) at other companies

ZymeworksZYME

72.8K—

Boston BeerSAM

46.9K+43.0%

Affiliated Managers GroupAMG

$34.38M+20.2%

ZymeworksZYME

$0—

Deckers Outdoor CorporationDECK

$2.28M+5.3%

HTF

Heartflow, Inc. Common StockHTFL

-$473K-271%

Other financials

Income statement

See full

Revenue$453.2M+2.8%

Gross profit$123.5M-1.3%

Operating income$36.5M-14.1%

Net income$30.4M-7.3%

EPS (diluted)$1.22-6.9%

Balance sheet

See full

Cash & equivalents$289.1M-3.6%

Total debt$50.6M+14.0%

Total equity$1.3B+6.7%

Total assets$1.8B+2.5%

Cash flow

See full

Operating cash flow$17.6M-37.8%

CapEx$8.9M+6.0%

Free cash flow$8.7M-56.3%

Valuation

See full

Market cap$2.05B-23.6%

Profitability

See full

Gross margin27.4%-1.3pp

Operating margin6.9%-2.6pp

Net margin6.4%—

FCF margin4.5%-1.1pp

Returns & leverage

See full

Return on equity8.8%—

Debt / equity0×0.0×

Current ratio3×+0.3×

Where this comes from

Reported directly by Innospec in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares.

The official record: Innospec’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innospec's issue of shares upon vesting of restricted stock units (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Innospec's issue of shares upon vesting of restricted stock units (in shares)?: Innospec (IOSP) reported issue of shares upon vesting of restricted stock units (in shares) of 135.6K in Q1 2026.